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unremarkable. He completed 13 years of formal educa-
tion and worked in the upper echelons of management at a 
professional firm.
The subject’s family history (Supplementary Fig. S1a) 
was notable for a father with multiple concussions and 
late-life seizures, alcoholism, impulsiveness, and poor 
decision-making. An older sibling with left arm hemihy-
pertrophy (Parkes-Weber Syndrome) was deceased after 
post-operative stroke. A younger sibling developed epi-
lepsy at age 19 and underwent frontal lobe resection sur-
gery at age 43; this individual experienced progressive 
difficulty with concentration and multitasking, qualifying 
for a diagnosis of mild cognitive impairment (MCI) in the 
executive domain.
On exam, the proband was 72 inches tall and weighed 
220 lb (BMI of 29.8). Skin exam revealed ungual fibromas 
and a shagreen patch. His neurological exam was normal 
except for an expansive mood, intrusive commentary, and 
jocularity verging on the inappropriate. Neuropsycho-
logical testing revealed impaired confrontational naming 
with mild deficits in semantic knowledge. Visual episodic 
memory, executive functioning, and information process-
ing speed were also impaired. Other cognitive domains 
were within normal limits for age. Deficits localized to the 
right greater than left temporal and frontal lobes. Magnetic 
resonance imaging (MRI) revealed corresponding areas of 
atrophy and white matter lesions (Fig. 1a). Electroencepha-
logram (EEG) was negative for epileptiform activity.
The proband met criteria for probable behavioral variant 
frontotemporal dementia (bvFTD), a sub-type of frontotem-
poral lobar degeneration (FTLD), based on early behavioral 
disinhibition, loss of empathy, perseverative behaviors, neu-
ropsychological profile, and MRI findings [12]. Given his 
family history, he was screened for known genetic causes of 
FTLD with no observed pathogenic variants. Therefore, the 
A 52-year-old right-handed man presented for the evalua-
tion of progressive emotional flattening, social withdrawal, 
and loss of empathy. Prior to symptom onset, his wife of 
21 years described him as “easy going, loving, kind, and 
generous.” As symptoms progressed, the subject began to 
alienate coworkers with unwelcome and persistent practical 
jokes. These disinhibited behaviors were accompanied by 
new, compulsive Internet usage. No language, visuospatial, 
memory, or motor symptoms were reported.
Past medical history included chronic headaches and 
multiple concussions but no seizures, psychiatric dis-
orders, or drug use. He denied cutaneous, dental, or 
renal abnormalities. His childhood development was 
Nicholas T. Olney and Carolina Alquezar have contributed 
equally to this work.
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proband and his affected sibling underwent whole-exome 
sequencing. Among variants identified, a novel frameshift 
mutation in one allele of the TSC1 gene, predicted to result 
in early termination of the TSC1/hamartin protein, was 
shared by the proband and his younger sibling (Fig. 1b, 
Supplementary Fig. S1b, c; Table S1).
TSC1/hamartin is an upstream inhibitor of mTOR, 
which regulates cell growth and protein degradation [8]. 
Fig. 1  Proband clinical MRI, novel TSC1 mutation, cell model of 
TSC1/hamartin haploinsufficiency, and neuropathology of a TSC1 
mutation carrier. a Magnetic resonance imaging (MRI) FLAIR 
sequences revealed severe atrophy of the right anterior temporal 
lobe, particularly the entorhinal/perirhinal cortices and inferior tem-
poral gyrus, as well as the hippocampus and amygdala. There was 
also involvement of the left anterior/mesial temporal lobe and the 
bilateral frontal and right parietal lobes. T2/FLAIR hyperintensi-
ties are seen within the subcortical white matter, some of which 
extended to the superolateral aspects of the lateral ventricles (arrow-
heads). These lesions can be seen in tuberous sclerosis or focal 
cortical dysplasias as a transmantle sign. b Sanger sequencing con-
firmed a novel frameshift variant in the TSC1 gene (NM_000368.4: 
c.62_63insTG: p. Arg22CysfsTer5) that segregated with the proband 
and affected sibling. c Representative micrographs of the enlarged 
cell body in the undifferentiated TSC1 heterozygous mutant SH-
SY5Y lines. Scale bars represent 50 microns. d Representative west-
ern blots showing decreased TSC1/hamartin and increased phopho- 
P70S6Kthr389, total tau, and phospho-tau levels in retinoic acid differ-
entiated TSC1 +/− SH-SY5Y cells. TDP-43 levels are unchanged. e–
g Fragment of frontal cortex resection from the proband’s sibling was 
received and stained for hyperphosphorylated tau, revealing patchy 
staining in neurons, glia, and surrounding neuropil. Scale bars repre-
sent 1000 (e), 250 (f), and 25 (g) microns
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To determine the significance of the TSC1 loss of func-
tion variant, CRISPR/Cas9 genome editing [6] was used 
to generate a cellular model of TSC1/hamartin deficiency 
in SH-SY5Y cells, a human neuroblastoma cell line that 
can be differentiated into neuronal-like cells [7] (Supple-
mentary Fig. S2a). We confirmed that these lines exhibited 
decreased TSC1/hamartin, increased cell size, and elevated 
P70S6K phosphorylation, consistent with mTOR over 
activity (Fig. 1c, Supplementary Fig. S2b, c). After reti-
noic acid (RA) differentiation, TSC1 +/− cells maintained 
lower levels of TSC1/hamartin and increased mTOR activ-
ity. Interestingly, the RA-differentiated TSC1 +/− lines 
accumulated phospho-tau and total tau. However, levels of 
TDP-43, another protein that aggregates in FTLD [2], were 
unchanged compared to control (Fig. 1d, Supplementary 
Fig. S2d–h).
Histological samples were obtained from the partial 
frontal lobe resection of the affected sibling, also a TSC1 
mutation carrier. Similar to SH-SY5Y model of TSC1 hete-
rozygosity, immunostaining of the resected tissue for phos-
phorylated tau revealed patchy neuropil staining as well as 
diffuse cytoplasmic staining of scattered neurons and glia, 
with variable intensity (Fig. 1e–g). No neurofibrillary tan-
gles, Pick bodies, glial inclusions, or other features of an 
inherited or sporadic tauopathy were observed. Sections 
were also stained for TDP-43, phospho-TDP-43, amyloid 
beta (Aβ), α-synuclein, and ubiquitin. Surprisingly, they 
did not demonstrate elevated immunoreactivity for any 
other neurodegenerative disease proteins (data not shown).
In this case report, we describe the first case of bvFTD 
in an adult with sub-clinical tuberous sclerosis complex 
(TSC) due to a novel TSC1 frameshift variant. Although 
TSC has been called an “infantile tauopathy” [13], TSC1 
mutations have not previously been implicated in age-asso-
ciated neurodegenerative disease. This report, therefore, 
potentially adds TSC1 to the list of genes that are impli-
cated in both a juvenile-onset lysosomal storage disease 
and adult-onset neurodegeneration. Others include GBA 
and ATP13A2 in Parkinson’s disease, CTSD in Alzhei-
mer’s disease, and PGRN in FTLD [10, 15]. The TSC1/
TSC2 complex normally inhibits mTOR activity, with loss 
of function mutations resulting in overactive mTOR and 
consequential increased protein synthesis and decreased 
protein degradation [3, 8, 9]. Strikingly, the decreased pro-
tein degradation seems selective for tau, as evidenced from 
both our cell-based and neuropathological data. This case 
now suggests that with age, accumulated tau can precipi-
tate neuron loss and neurodegeneration. It also raises the 
intriguing possibility that tau metabolism is selectively reg-
ulated by the mTOR pathway. Our data suggest that TSC1 
loss of heterozygosity, which is necessary for TSC-related 
tumors [11], is not required for TSC1-related tau accumula-
tion and neurodegeneration.
Our findings could be highly significant to the care of 
TSC patients. Many features of tuberous sclerosis associ-
ated neuropsychiatric disorders (TAND) [4, 5], including 
obsessive behavior, attention deficits, altered eating, impul-
sivity, memory loss, and language dysfunction, overlap 
with bvFTD criteria. Thus, these two clinical entities may 
represent overlapping disorders precipitated by progressive 
tau pathology. Additional sequencing of the TSC1/2 genes 
in FTLD cohorts, use of new tau-based PET imaging, and 
review of neuropathological specimens from older TSC 
patients may further support the association between TSC, 
TAND, and FTLD.
This study extends the relationship between mTOR and 
tau metabolism [1, 16] to include a potential age-related 
component. How does aging alter the TSC1/mTOR axis 
to potentially contribute to the development of neurode-
generation? Why do tau and phospho-tau accumulate, 
while related proteins that undergo chaperone medi-
ated autophagy, such as TDP-43, do not? Do TSC2 muta-
tions also link to age-related tauopathies? These questions 
and others are stimulated by our report. In the meantime, 
this study supports trials of rapamycin analogs which are 
already underway for neurodegeneration [14], and moves 
us towards a personalized medicine future in which sub-
populations of tauopathy patients may be selectively 
responsive to this therapeutic approach.
Acknowledgements This work is supported by the Rainwater 
Tau Consortium and NIH/NIA (P50AG023501, P01AG019724, 
T32AG023481-11S1, and P50 AG1657303). Additional support was 
provided by the Ramón Areces Foundation (C.A.), the Paul G. Allen 
Family Foundation (A.W.K.), NIH/NIA RC1 AG035610 (G.C.), John 
Douglas French Alzheimer’s Foundation (G.C.), National Alzheimer’s 
Coordinating Center Junior Investigator Award (R.S.D.), ASNR Alz-
heimer’s Imaging Research Grant Program (R.S.D.), RSNA Resident 
Fellow grant (R.S.D.), and NIH/NIDA grant U24DA041123 (R.S.D.). 
We thank Thomas Pittman and William Markesbury from the Univer-
sity of Kentucky for sharing the pathological specimens. We thank the 
Tau Consortium Stem Cell group for technical advice and support.
Author contributions A.W.K., B.L.M, G.C., and W.W.S designed 
the study. N.T.O., C.A., E.M.R, A.L.N., J.C.F., A.M.K., J.B.T., 
M.L.S., M.D.D., A.R.A., V.A.v.B., D.R.D., E.H.S, G.A.J., W.P.D., 
R.S.D., B.L.M., A.W.K., G.C., and W.W.S. were responsible for data 
acquisition and analysis. N.T.O., C.A., E.M.R., J.C.F., J.B.T., R.S.D., 
and A.N.L. created the figures. N.T.O., C.A., W.W.S, G.C., B.L.M., 
and A.W.K. wrote the manuscript.
Compliance with ethical standards 
Conflict of interest Dr. Seeley reports personal fees from Merck, Inc., 
personal fees from Bristol Myers-Squibb, outside the submitted work. 
Dr. Miller has served as an Advisor/Director to The Tau Consortium, 
The John Douglas French Foundation, The Larry L. Hillblom Founda-
tion, Medical Advisory Board, National Institute for Health Research, 
Cambridge Biomedical Research Centre and its subunit, the Biomedi-
cal Research Unit in Dementia (UK); he has served as an External 
Advisor to University of Washington ADRC, Stanford University 
816 Acta Neuropathol (2017) 134:813–816
1 3
ADRC, and University of Pittsburgh ADRC; he receives royalties from 
Cambridge University Press, Guilford Publications, Inc., and Neuro-
case. All other authors have no conflicts of interest to report.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda 
MF, Silva AJ, Oddo S (2013) mTOR regulates tau phospho-
rylation and degradation: implications for Alzheimer’s disease 
and other tauopathies. Aging Cell 12:370–380. doi:10.1111/
acel.12057
 2. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, 
Hatanpaa KJ, White CL 3rd, Schneider JA, Grinberg LT, Hal-
liday G et al (2007) Neuropathologic diagnostic and nosologic 
criteria for frontotemporal lobar degeneration: consensus of the 
Consortium for Frontotemporal Lobar Degeneration. Acta Neu-
ropathol (Berl) 114:5–22
 3. Crino PB (2016) The mTOR signalling cascade: paving new 
roads to cure neurological disease. Nat Rev Neurol 12:379–392. 
doi:10.1038/nrneurol.2016.81
 4. Curatolo P, Moavero R, de Vries PJ (2015) Neurological and 
neuropsychiatric aspects of tuberous sclerosis complex. Lancet 
Neurol 14:733–745. doi:10.1016/S1474-4422(15)00069-1
 5. de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, 
Ess KC, Hook D, King BH, Sahin M, Jansen A (2015) Tuber-
ous sclerosis associated neuropsychiatric disorders (TAND) and 
the TAND Checklist. Pediatr Neurol 52:25–35. doi:10.1016/j.
pediatrneurol.2014.10.004
 6. Doudna JA, Charpentier E (2014) Genome editing. The new 
frontier of genome engineering with CRISPR-Cas9. Science 
346:1258096. doi:10.1126/science.1258096
 7. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena 
V, Gallego C, Comella JX (2000) Sequential treatment of SH-
SY5Y cells with retinoic acid and brain-derived neurotrophic 
factor gives rise to fully differentiated, neurotrophic factor-
dependent, human neuron-like cells. J Neurochem 75:991–1003
 8. Laplante M, Sabatini DM (2012) mTOR signaling in growth 
control and disease. Cell 149:274–293. doi:10.1016/j.
cell.2012.03.017
 9. Lipton JO, Sahin M (2014) The neurology of mTOR. Neuron 
84:275–291. doi:10.1016/j.neuron.2014.09.034
 10. Nixon RA (2013) The role of autophagy in neurodegenerative 
disease. Nat Med 19:983–997. doi:10.1038/nm.3232
 11. Qin W, Chan JA, Vinters HV, Mathern GW, Franz DN, Tail-
lon BE, Bouffard P, Kwiatkowski DJ (2010) Analysis of 
TSC cortical tubers by deep sequencing of TSC1, TSC2 
and KRAS demonstrates that small second-hit mutations 
in these genes are rare events. Brain Pathol 20:1096–1105. 
doi:10.1111/j.1750-3639.2010.00416.x
 12. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer 
JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike 
CU et al (2011) Sensitivity of revised diagnostic criteria for 
the behavioural variant of frontotemporal dementia. Brain 
134:2456–2477. doi:10.1093/brain/awr179
 13. Sarnat HB, Flores-Sarnat L (2015) Infantile tauopathies: hemi-
megalencephaly; tuberous sclerosis complex; focal cortical dys-
plasia 2; ganglioglioma. Brain Dev 37:553–562. doi:10.1016/j.
braindev.2014.08.010
 14. Siman R, Cocca R, Dong Y (2015) The mTOR inhibitor rapamy-
cin mitigates perforant pathway neurodegeneration and synapse 
loss in a mouse model of early-stage alzheimer-type tauopathy. 
PLoS ONE 10:e0142340. doi:10.1371/journal.pone.0142340
 15. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia 
L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF 
et al (2012) Strikingly different clinicopathological phenotypes 
determined by progranulin-mutation dosage. Am J Hum Genet 
90:1102–1107. doi:10.1016/j.ajhg.2012.04.021
 16. Tang Z, Ioja E, Bereczki E, Hultenby K, Li C, Guan Z, Winblad 
B, Pei JJ (2015) mTor mediates tau localization and secretion: 
implication for Alzheimer’s disease. Biochim Biophys Acta 
1853:1646–1657. doi:10.1016/j.bbamcr.2015.03.003
